Mike, it's great to have you on the show. Welcome. What does this partnership with OpenAI enable and how quickly do you expect to realize results.Thank you very much, Morgan, for having me. It's a very exciting day for our company because in a nutshell, you could say this is a day where science meets speed and scale at the same time. We're partnering with OpenAI on the back of a huge data set that Novo Nordisk holds, probably second to none when it comes to diabetes and obesity, and a company technological ...

Core Viewpoint - The GLP-1 market is highly competitive, with Novo Nordisk and Eli Lilly as key players, each offering different products and pricing strategies to capture market share. Group 1: Product Offerings and Pricing - Novo Nordisk has launched a higher dose version of Wegovy in the US, priced at $399 for cash customers and about $25 for those with insurance, undercutting Eli Lilly's Zepbound by approximately $100 [1] - Eli Lilly's Zepbound and Mounjaro are viewed as market leaders due to their efficacy, with tirzepatide (Zepbound) being considered the most effective product currently available [4][5] - Novo Nordisk has also introduced a pill version of its product, expected to be available in 2026, expanding its range of injectables [2] Group 2: Market Dynamics and Competition - Efficacy is the primary driver of market share, with Zepbound currently holding a superior position unless a product demonstrates significantly increased effectiveness [5][6] - Eli Lilly is seen as having a strong pipeline of future products, including retatrutide, which may offer higher weight loss percentages and cater to more extreme cases [7][8] - As competition increases, prices are expected to decline, leading to higher demand, particularly among cash-paying consumers who are more price-sensitive [10][12] Group 3: Company Outlooks - Eli Lilly is on a positive outlook due to its growth story, investments in manufacturing and R&D, and improving balance sheet [14][15] - Novo Nordisk is currently rated with a stable outlook, having started with lower leverage compared to Eli Lilly [16] - The injectables are expected to remain the primary treatment method, despite the introduction of pill forms, as they are more effective and have established usage among diabetes patients [18][19] Group 4: Future Developments - Other pharmaceutical companies, such as Amgen and Pfizer, are entering the GLP-1 market with products that may require less frequent dosing, although none currently appear to surpass Zepbound in effectiveness [21][22][23]

One of the biggest holdouts for patients looking to start on GLP1s is the fact that it's long been an injection. >> Between affordability and kind of having a fear of needles, it was something that I just dragged my feet on. >> Jane Zuckerman is one of the many patients I've spoken to in recent weeks that have started on the Begovi pill.It's drug maker Novaortis new oral weight loss drug. The company said more than half a million prescriptions have been written for the pill during the first month of its lau ...

One of the biggest holdouts for patients looking to start on GLP1s is the fact that it's long been an injection. >> Between affordability and kind of having a fear of needles, it was something that I just dragged my feet on. >> Jane Zuckerman is one of the many patients I've spoken to in recent weeks that have started on the Begoi pill.It's drug maker Novaorisk's new oral weight loss drug. The company said more than half a million prescriptions have been written for the pill during the first month of its la ...

Another pill to fight obesity won US approval, pitting Lilly’s Foundayo against Novo’s Wegovy pill in the race to dominate a market worth billions. Patients and consumers may also be winners, as prices fall and selection expands. https://t.co/1upjiYnPww ...

The FDA approved Eli Lilly’s new weight-loss pill, setting up a fight with rival Novo Nordisk over the next front in the booming market https://t.co/1j0gqhoXlH ...

Eli Lilly & Co.’s weight-loss pill won US approval, ratcheting up pressure on Novo Nordisk A/S, which launched an obesity pill earlier this year. https://t.co/FDknJHod96 ...

Core Insights - Novo Nordisk's stock rose by as much as 4% following a recommendation from England's drug price regulator to use its drug Wegovy for preventing heart attacks and strokes [1] - The recommendation from the National Institute for Health and Care Excellence (NICE) will significantly increase access to Wegovy through the National Health Service (NHS) in England [2] - NICE has recommended semaglutide, the active ingredient in Wegovy, for adults with a BMI of at least 27 who have a history of heart attack, stroke, or serious circulation issues [3] Group 1 - Novo Nordisk's shares were observed to be up 2% in morning trading, reflecting a positive market response [3] - The broader market, represented by the pan-European blue-chip index Stoxx 600, also saw an increase of 2.1% [3]

Healthcare - The UK's NICE has recommended Novo Nordisk's Wegovy (2.4mg) for reducing the risk of major cardiovascular events in adults with cardiovascular disease and obesity, marking a significant milestone for GLP-1 medications in cardiovascular prevention [2][9] - The final guidance for the treatment is expected by the end of April 2026, with plans for integration into existing NHS cardiovascular care pathways, potentially broadening the market for weight-loss drugs [3][9] Trade - The U.S. government is launching a digital refund portal for $166 billion in duties collected under the Trump administration's tariffs, following a Supreme Court ruling that deemed these tariffs unlawful [4][9] - The Treasury is adopting a "Digital Only" payment model via the ACE portal to manage the volume of claims, emphasizing the need for businesses to ensure their ACH setup is active [5] Energy & Tech - Microsoft and Engine No. 1 are in discussions for a $7 billion natural gas-fired power project in Texas, aimed at providing dedicated electricity for a large-scale data center campus [6][9] - Chevron has clarified that no commercial terms have been finalized for its participation in the project, which reflects a trend of tech companies securing energy resources for AI workloads [7] Asia-Pacific - Australia's S&P/ASX 200 index rose 1.6% to 8,618.20, supported by government signals of assistance for the private sector, including potential payment deferrals and loan restructuring [8][9] - The Australian government signed a Memorandum of Understanding with Anthropic to collaborate on AI safety and economic data tracking, marking the first arrangement under the National AI Plan [10] Commodities & Crypto - Gold prices have maintained a three-day gain amid shifting geopolitical tensions, with President Trump's comments suggesting a potential end to hostilities with Iran, leading to a drop in crude oil prices [11] - CoinShares is set to begin trading on the Nasdaq following a SPAC merger, valuing the crypto manager at approximately $1.2 billion and enhancing its presence in the U.S. market [12]

Core Viewpoint - The UK's drug cost-effectiveness watchdog, NICE, has recommended Novo Nordisk's Wegovy for reducing the risk of serious heart problems or strokes in obese or overweight adults, marking it as the first GLP-1 drug endorsed for this purpose [1][2]. Group 1: Drug Approval and Recommendations - Wegovy, at a 2.4-milligram dose, will be available through the National Health Service (NHS) following NICE's recommendation [2]. - The drug will be integrated into existing cardiovascular treatment pathways, allowing healthcare providers to consider it alongside standard therapies for secondary prevention of heart issues in overweight or obese adults [2]. Group 2: Clinical Evidence - NICE's recommendation was based on a study involving over 17,600 participants, demonstrating that Wegovy reduced the risk of major cardiovascular events by 20% compared to a placebo [3]. - In 2024, Wegovy received UK regulatory approval to reduce the risk of major cardiovascular events in obese or overweight adults with preexisting heart disease, although initial access was limited to patients paying out-of-pocket [3]. Group 3: Market Context - Approximately one in four adults in the UK is estimated to be living with obesity, highlighting a significant market for weight-loss and cardiovascular drugs [4]. - Eli Lilly, a competitor, has raised the UK list price for its weight-loss drug Mounjaro by up to 170% last year, indicating competitive pricing pressures in the market [5].